Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

AZD3293

- PMLiVE

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

- PMLiVE

Lilly to acquire AtaiBeckley in deal worth $2.8bn

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

- PMLiVE

Veradermics’ oral treatment for female pattern hair loss delivers positive study results

Pattern hair loss affects around 30 million women and 50 million men in the US

- PMLiVE

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Cuttsy + Cuttsy

- PMLiVE

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved

The real-world findings support the long-term benefits of continuous treatment

- PMLiVE

Alzheimer’s groups call for urgent global focus on women’s brain health

New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association

- PMLiVE

AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

The company will gain a novel oral treatment for lung cancer

- PMLiVE

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

Cuttsy + Cuttsy

- PMLiVE

The value: why localisation pays off across global trials

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.

Cuttsy + Cuttsy

- PMLiVE

Biogen to acquire RayThera in $1bn deal

The acquisition will expand the company’s immunology pipeline

- PMLiVE

The solution: Good localisation doesn’t feel translated

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Cuttsy + Cuttsy

It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment

ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links